Lantern Pharma Inc.: Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001

AI Briefing

• – Lantern Pharma and Starlight Therapeutics receive FDA clearance for Phase 1 trial of STAR-001 for pediatric CNS cancer.
• – The trial will evaluate STAR-001 as monotherapy and in combination with spironolactone in children with relapsed or refractory CNS malignancies.
• – The planned trial will focus on ATRT, DIPG, and other CNS malignancies.